Study Stopped
The wild rice cereal development was stopped, so the trial was also withdrawn prior to starting.
Blood Glucose Response of Novel Wild Rice Enhanced Food Products (Trial 2)
ABWE
Assessing the Blood Glucose Response of Novel Wild Rice Enhanced Food Products (ABWE) Study
1 other identifier
interventional
N/A
1 country
1
Brief Summary
The goal of this acute double-blind cross over trial to test the effects of different wild rice cereal products compared to products currently on the market on glycaemic control. The main questions it aims to answer are:
- consent to attend 6 study visits being 2.5 hours each
- come to each visit fasted for at least 10-12 hours.
- complete a Motivation to Eat VAS following each blood measure
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Sep 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 4, 2024
CompletedFirst Posted
Study publicly available on registry
July 12, 2024
CompletedStudy Start
First participant enrolled
September 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2026
ExpectedAugust 24, 2025
August 1, 2025
7 months
July 4, 2024
August 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The effects of different wild rice products compared to products currently on the market on glycaemic control.
Finger stick blood glucose will be measured throughout each session.
Capillary blood glucose will be measured at 0 (baseline) and then 15, 30, 45, 60, 90 and 120 mins after the first bite of treatment.
Secondary Outcomes (1)
To measure the palatability of the wild rice products following consumption.
VAS measuring palatability will be completed right after the consumption of the treatments.
Study Arms (6)
Consumption of 1 of 2 control rice cereal products
ACTIVE COMPARATORThis arm will provide one of the 2 white rice control products and there will be a minimum of three days separating each visit.
Final consumption of 1 of 2 control rice cereal products
ACTIVE COMPARATORThis arm will provide one of the 2 white rice control products and there will be a minimum of three days separating each visit.
Consumption of 1 of 4 rice products
EXPERIMENTALThis arm will provide 1 of the 4 randomly assigned rice products to the participant and there will be a minimum of three days separating each visit.
Second consumption of 1 of 4 rice products
EXPERIMENTALThis arm will provide 1 of the 4 randomly assigned rice products to the participant and there will be a minimum of three days separating each visit.
Third consumption of 1 of 4 rice products
EXPERIMENTALThis arm will provide 1 of the 4 randomly assigned rice products to the participant and there will be a minimum of three days separating each visit.
Final consumption of 1 of 4 rice products
EXPERIMENTALThis arm will provide 1 of the 4 randomly assigned rice products to the participant.
Interventions
One serving size (140g) of whole white rice cereal will be provided. Preparation will be consistently maintained throughout.
One serving size (140g) of whole white rice cereal with 125ml of milk will be provided. Preparation will be consistently maintained throughout.
One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) with 125ml of milk will be provided. Preparation will be consistently maintained throughout.
One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) will be provided. Preparation will be consistently maintained throughout.
One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) with a 10% added purple powder (sweet potato) will be provided. Preparation will be consistently maintained throughout.
One serving size (140g) of novel cereal (40% Canadian wild rice, 50% fava bean blend) and 10% purple powder (sweet potato) with 125 ml milk. Preparation will be consistently maintained throughout.
Eligibility Criteria
You may qualify if:
- Participant is willing and able to give informed consent for participation in the trial
- Male or female between 18-50 years old
- BMI range in between 18.9-29.9 kg/m2
- Fasting glucose \<5.6 mmol/L
- Usually eat breakfast
- Participant must receive at least two doses of COVID-19 vaccine that have been recognized by Winnipeg Regional Health Authorities.
- In the Investigator's opinion is able and willing to comply with all trial requirements
You may not qualify if:
- Fasting glucose ≥ 5.6 mmol/L or \<3.5 mmol/L
- Female participant who is pregnant, lactating or planning pregnancy during the course of the trial
- Participants who indicate that they could not finish study treatments within 10 minutes
- Use of medication or supplements that may influence carbohydrate metabolism, including, not limit to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of screening visit
- History of disordered eating, AIDS, hepatitis, a history of clinically important endocrine (including Type I and Type II diabetes mellitus), cardiovascular (including but not limit to atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, biliary or GI disorders
- Intolerance or allergic reaction to rice
- Existing restrictive dietary habits (such a vegan, low carbohydrate/keto) Date and version No: December 12 , 2022, Version 2 Page 7 of 15
- History of hypertension
- History of cancer within the last two years (except for non-melanoma skin cancer)
- Recent history (within 12 month of screening) or current consumption of \>14 drinks per week, (1 drink = 12oz of beer, 5oz of wine or 1.5oz distilled spirits)
- Body weight change over 3.5kg for the past 3 months
- Participants who have participated in another research trial involving an investigational product in the past 12 weeks
- Had significant physical trauma or major surgery in the past 3 month or had trauma or major surgery in the past 3 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dylan MacKaylead
- Mitacscollaborator
Study Sites (1)
Chronic Disease Innovation Centre, Seven Oaks Hospital
Winnipeg, Manitoba, R2V 3M3, Canada
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dylan MacKay, PHD
University of Manitoba
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Masking Details
- The allocation of this intervention order will be blinded for the investigators and the participants. Treatment will be given blinded names, such as A and B, but it may be possible to determine what each treatment is due to its appearance, however we will not be informing the participants what the treatments are. The study staff who will be preparing and overseeing the treatments may not be blinded due to the different appearances of the treatments. However, the staff that will conduct the trial results analyses will not be un-blinded until the analyses are complete.
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
July 4, 2024
First Posted
July 12, 2024
Study Start
September 1, 2025
Primary Completion
March 30, 2026
Study Completion (Estimated)
September 1, 2026
Last Updated
August 24, 2025
Record last verified: 2025-08